SCHEMBL29672011

SCHEMBL29672011

CN1CCN(Cc2ccc(N)cc2Cl)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
TDP1 Q9NUW8 2/20 0.64
KDM4E B2RXH2 2/20 0.64
POLB P06746 1/20 0.64
NR1H2 P55055 1/20 0.62
LMNA P02545 1/20 0.60
CHKA P35790 2/20 0.58
MAPT P10636 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
RAD52 P43351 1/20 0.55
SIGMAR1 Q99720 1/20 0.49
CYP2A13 Q16696 1/20 0.46
MC4R P32245 1/20 0.46
ADORA1 P30542 1/20 0.44
METAP2 P50579 1/20 0.44
ACHE P22303 2/20 0.44
CA2 P00918 1/20 0.43
NCF1 P14598 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL591420 1.00 ALDH1A1 (0.64) ALDH1A1TDP1KDM4EPOLBNR1H2
SCHEMBL4297559 0.87 LMNA (0.60) ALDH1A1TDP1KDM4EPOLBNR1H2
SCHEMBL4935736 0.87 MAPT (0.57) ALDH1A1TDP1KDM4EPOLBNR1H2
SCHEMBL2208032 0.85 ACHE (0.60) ALDH1A1TDP1KDM4EPOLBNR1H2
SCHEMBL2656580 0.83 KDM4E (0.88) ALDH1A1TDP1KDM4EPOLBCHKA
SCHEMBL3859176 0.83 ACHE (0.58) ALDH1A1TDP1KDM4EPOLBCHKA
SCHEMBL17918745 0.82 ALDH1A1 (0.66) ALDH1A1TDP1KDM4EPOLBNR1H2
SCHEMBL4758225 0.82 NR1H2 (0.64) ALDH1A1TDP1KDM4EPOLBNR1H2
SCHEMBL3862744 0.81 ALDH1A1 (0.59) ALDH1A1TDP1KDM4EPOLBMAPT
SCHEMBL3916828 0.81 ALDH1A1 (0.51) ALDH1A1TDP1KDM4EPOLBNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114573567-B Indazole cyclotriazole compound and preparation method and application thereof 西安交通大学 2023-05-02 CN claimed
CN-114573567-A Indazole cyclic triazole compound and preparation method and application thereof 西安交通大学 2022-06-03 CN claimed
US-20250361232-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICALS USA INC (US) 2025-11-27 US disclosed
CN-114573567-B Indazole cyclotriazole compound and preparation method and application thereof 西安交通大学 2023-05-02 CN disclosed
WO-2022226182-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-27 WO disclosed
CN-114573567-A Indazole cyclic triazole compound and preparation method and application thereof 西安交通大学 2022-06-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361232-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS MAP4K2, MAP3K19, MAP3K1 ALDH1A1 980/4885TDP1 1725/4885KDM4E 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.